RxDoctor Payments Data

Ronald Suh, MD

Urology · Avon, INNPI 1164436523

Payments from drug & device makers

What this record shows

The money is spread across several categories — speaking fees (48.2%), food and beverage and travel and lodging — rather than concentrated in one kind of arrangement. 47 manufacturers reported payments, led by Endo Pharmaceuticals Inc. at 58.4% of the total. Reporting peaked in 2019 at $15,498 and has fallen 84.7% since, to $2,373 in 2025.

$24,373in general payments, 2019–2025

Across 379 payments — averaging $64.31 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Endo Pharmaceuticals Inc.$14K
  • Avyxa Pharma, LLC$1K
  • Bayer$996
  • Johnson & Johnson$874
  • Astellas Pharma US Inc$577
  • Sumitomo Pharma America, Inc.$533
  • plus $6K from 41 others
$100,715in research payments, 2019–2025

Across 74 payments — averaging $1361.01 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

  • Ferring Pharmaceuticals AS$38K
  • Ferring International Pharmascience Center US$20K
  • Sumitomo Pharma America, Inc.$19K
  • Pfizer$14K
  • Astellas Pharma Global Development$3K
  • Medivation LLC.$3K
  • plus $3K from 1 others

What the payments were for

  • Consulting fees$4402%
  • Speaking & faculty fees$11,75048%
  • Travel & lodging$2,36510%
  • Food & beverage$9,29938%
  • Education$5192%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$24,373 in reported general payments places this provider in the 85th percentile of 272 urology providers in Indiana.

See all urology providers in Indiana

Medicare billing

Part B allowed, 2024
$185,531
Medicare patients
534
Services billed
4,980

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OrgovyxRelugolix28$76,391
MyrbetriqMirabegron77$75,326
GemtesaVibegron56$58,562
Abiraterone Acetate23$30,819
XyostedTestosterone Enanthate28$17,094
Tamsulosin Hcl467$6,384
Finasteride279$4,366
Testosterone Cypionate166$4,264
Potassium Citrate ErPotassium Citrate41$3,636
Silodosin38$2,830
Nitrofurantoin Mono-MacroNitrofurantoin Monohyd/M-Cryst77$2,484
Trospium Chloride27$2,326
Testosterone11$1,718
Dutasteride28$1,594
Cephalexin140$1,222

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Sumitomo Pharma America, Inc.Orgovyx, Gemtesa$533$134,95384 claims
Astellas Pharma US IncMyrbetriq$577$75,32677 claims
Janssen Scientific Affairs, LLCAbiraterone Acetate$168$30,81923 claims
Antares Pharma, Inc.Xyosted$128$17,09428 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 272 urology providers in Indiana.

Other urology in Avon

See the full list for Indiana

Where these figures come from

Is this you, or does something look wrong? →